ArticleScientific reports2026
Signaling network exploration of microRNA140-5p in response to TMJ-OA pathological changes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
MicroRNA140-5p has been implicated in temporomandibular joint osteoarthritis (TMJ-OA), though its precise mechanistic role remains unclear. This study investigates the molecular mechanisms underlying microRNA140-5p-mediated inflammatory responses in TMJ-OA. In vitro, mandibular condylar chondrocytes (MCCs) were treated with IL-1β and transfected with small interfering RNA (siRNA) targeting Smad3, a direct target of microRNA140-5p. Expression of inflammatory cytokines was assessed via Western blotting and RT-qPCR. In vivo, a TMJ-OA model was established in Sprague-Dawley (SD) rats, followed by intra-articular injection of antagomir140-5p into the superior joint cavity. Histopathological and immunohistochemical (IHC) analyses were performed using hematoxylin-eosin (HE) staining. Our findings demonstrate that IL-1β treatment upregulated microRNA140-5p expression in MCCs. Overexpression of microRNA140-5p suppressed chondrocyte proliferation and cartilage formation while promoting apoptosis. Conversely, antagomir140-5p administration preserved cartilage integrity in TMJ-OA, restoring expression of SOX9, COL2A1, SMAD3, and TGF-β3, while suppressing inflammatory mediators such as RUNX2 and NF-κB. These findings suggest that the abnormal expression of microRNA-140-5p in condylar cartilage may reflect the pathological progression of temporomandibular joint osteoarthritis, with its potential mechanism likely mediated through regulation of the TGF-β/SMAD/SOX/NF-κB signaling axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.